Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Quintiles to fund an adaptive clinical trial to develop breast cancer therapies

Quintiles Transnational : 18 April, 2011  (Company News)
Quintiles is to contribute a total of $2.6 million over four years to support I-SPY 2, an adaptive clinical trial designed to develop breast cancer therapies twice as quickly and at one-fifth the cost of current methods.
Current development costs typically exceed $1 billion and take 12 to 15 years to bring a single drug to market.

The I-SPYi 2 clinical trial involves 800 patients with advanced breast cancer at time of primary diagnosis. It employs innovative adaptive trial design and genetic and biological markers from individual patients’ tumours to screen multiple investigational therapies simultaneously. The evaluation of multiple drugs concurrently allows investigators to quickly measure effectiveness.

The design of the I-SPY 2 trial represents a major advance in breast cancer research with promising implications for other cancers and other diseases. Quintiles will make its grant in support of I-SPY 2 through QuantumLeap Healthcare Collaborative, a 501(c)(3) non-profit foundation and a co-project manager of the trial.

“Quintiles’ $2.6 million grant and our joining the I-SPY 2 management consortium reflect the company’s unwavering commitment to patients,” said Dennis Gillings, CBE, Quintiles Chairman and Chief Executive Officer. “Multi-party collaboration, adaptive trial design, Biomarker use, and point-of-care data access are major steps in the right direction. Quintiles is proud to be part of this revolutionary effort.”

The Foundation for the National Institutes of Health is the sponsor of I-SPY 2 while the US FDA, National Cancer Institute and 20 leading academic cancer centers are collaborators in the effort. Quintiles joins The Safeway Foundation, QuantumLeap Healthcare Collaborative, several biopharmaceutical companies and individual donors as supporters.

Anna Barker, former Deputy Director of the National Cancer Institute (NCI), an original designer of I-SPY 2 and current Board Member of QuantumLeap, said: “We welcome Quintiles’ financial commitment and its support of our trial. I-SPY 2 represents the best of what we know in science and in the regulatory process. As the leading biopharmaceutical services organization, Quintiles brings the best in clinical trial management practices to this effort to dramatically reduce the time and cost of bringing new therapies to market.”

The study’s Co-principal Investigator, Laura Esserman, MD, of the University of California, San Francisco, said: “Because Quintiles works with hundreds of biopharmaceutical companies and healthcare organizations around the world, it can help disseminate I-SPY 2 innovations. We’ve set up a system where everyone can learn more quickly. Our goal is to reduce costs and time-to-market for new drugs that can make a difference in patients’ lives, first for women with breast cancer, then for other cancers as well.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo